Veritas Capital outbids CVC with £1.65 bn cash offer for Bodycote, valuing deal at ≈£1.85 bn
Veritas Capital raised its bid to 940 pence per share, a cash consideration of £1.65 bn that lifts the enterprise value of the UK‑listed heat‑treatment specialist to about £1.85 bn and puts the US firm ahead of rival CVC Advisers.
Veritas Capital’s revised cash offer of 940 pence per Bodycote share values the transaction at roughly £1.85 bn, outbidding rival private‑equity bidder CVC Advisers, according to Private Equity Wire (PEW) and a Bloomberg report.
Deal terms and valuation
The US‑based private‑equity firm agreed to pay a cash consideration of £1.65 bn for the acquisition of Bodycote, a UK‑listed engineering specialist that provides heat‑treatment and surface‑coating services. The offer price of 940 pence per share was disclosed in the announcement on 2 September 2026. Adding the target’s net debt brings the enterprise value of the transaction to approximately £1.85 bn (PEW). Both figures are presented as of the announcement date and are not adjusted for any subsequent market movements.
Veritas Capital is being advised by Lazard on the transaction, while Bodycote has retained a consortium of advisers – Barclays, Goldman Sachs, Gleacher Shacklock and Jefferies – to represent its shareholders (packet key facts).
| Metric | Value |
|---|---|
| Cash consideration | £1.65 bn |
| Offer price per share | 940 pence |
| Enterprise value (incl. debt) | ≈£1.85 bn |
| Share price reaction | +4.4 % |
Market reaction
Bodycote’s shares rose as much as 4.4 % in the immediate post‑announcement trading session, trading above the offer price of 940 pence. The price movement suggests investors see either a premium over the bid or the possibility of a further competing proposal from CVC (packet supporting claim “Bodycote shares climbed as much as 4.4 % after the announcement”). The rise was measured as a percentage increase from the pre‑announcement closing price; no absolute price level is provided in the packet.
Company backgrounds
Veritas Capital is a US private‑equity firm founded in 1992 and headquartered in New York City. The packet supplies only basic corporate data from Wikidata and notes that details such as the chief executive and employee headcount should be confirmed from the firm’s own filings before publication.
Bodycote, incorporated in 1923 and headquartered in Macclesfield, United Kingdom, is listed on the London Stock Exchange. It operates in the engineering sector, specialising in heat‑treatment and surface‑coating services for industrial customers. As with Veritas, the packet does not provide current executive or staffing figures, and the research notes a need for verification.
Timeline of the bidding process
- 2 September 2026 – Veritas Capital announced a revised cash offer of 940 pence per share, valuing Bodycote at roughly £1.85 bn and stating that the bid now exceeds the competing proposal from CVC Advisers (packet timeline).
- Prior to the announcement – Both Veritas and CVC had tabled earlier offers, but the packet does not disclose their amounts or dates.
- Post‑announcement – Bodycote’s share price rose 4.4 % and the market is awaiting confirmation of whether CVC will submit a further counter‑bid (packet supporting claim).
Implications for stakeholders
For Bodycote shareholders, the cash offer represents a definitive price of 940 pence per share, but the premium relative to the pre‑announcement market price is not quantified in the packet. The share‑price uplift indicates that at least a portion of investors view the offer as attractive, though the fact that the stock traded above the offer price hints at expectations of a higher bid.
From a financing perspective, the cash consideration of £1.65 bn will likely be funded through a combination of Veritas’s existing capital and debt facilities, although the packet does not detail the financing structure. The inclusion of Bodycote’s debt in the enterprise‑value calculation suggests that the acquirer will assume the target’s liabilities.
Advisers on both sides play a pivotal role: Lazard’s involvement on the buyer side signals a structured approach to valuation and negotiation, while the consortium of UK banks advising Bodycote indicates a thorough review of the offer’s fairness for shareholders.
Outstanding questions
The packet notes that the auction may not yet be closed, with CVC reportedly evaluating its options. No statement from CVC is included, so the likelihood of a higher counter‑offer remains uncertain. Additionally, the exact premium over Bodycote’s last closing price, the post‑deal capital structure, and any regulatory approvals required are not disclosed.
Finally, the identities of the chief executives of both Veritas Capital and Bodycote, as well as their employee counts, are absent from the verified material. The research packet explicitly cautions that these background details should be confirmed from primary sources before publication.
What comes next?
Assuming no further competing bid, the transaction will move into a definitive‑agreement phase, followed by shareholder approval and any required antitrust clearances. The timeline for closing is not provided, but typical UK take‑over processes can span several weeks to months after the offer is accepted.
Investors should monitor Bodycote’s share price for any deviation from the offer level, watch for a formal statement from CVC Advisers, and await filings that will disclose the final terms of the deal, including financing details and any post‑closing integration plans.